ORIGIO a/s→CooperSurgical (CooperCompanies)
Acquisition · Cash · COO · announced Jun 4, 2012
Announced
Jun 4, 2012
Closed
Jul 11, 2012
Economics
Cash()
Pre-deal · pre-deal mark: 2012, year precision · rounding grid ±$100M · Cooper Companies 10-K filing, SEC EDGAR — ORIGIO acquisition
~NOK 1,159M enterprise value (~$147M net of cash acquired)
Target
ORIGIO a/s
Fertility · Fertility science
HQ Måløv, Denmark · Founded 2005
Global IVF medical device company — culture media, micro-tools, and labware for fertility treatment
- SEC EDGAR - CooperCompanies 10-K (FY2012, acquisition details)
- Oslo Stock Exchange - ORIGIO tender offer (Jun 2012)
Acquirer
CooperSurgical (CooperCompanies) (COO)
Fertility
HQ Trumbull, CT
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Established CooperSurgical as global IVF device leader — ORIGIO's culture media and labware complemented existing fertility portfolio
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR — CooperCompanies 10-K (FY2012)
SEC EDGAR filings (ticker locator)Tertiary (trade / analyst)
Oslo Stock Exchange tender offer (Jun 2012)
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/711404/000119312512257770/d362335d8k.htm
Open source
Limitations
- ~NOK 1,159M enterprise value (~$147M net of cash acquired)
- Pre-deal valuation sourced from: Cooper Companies 10-K filing, SEC EDGAR — ORIGIO acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Other verified deals by CooperSurgical (CooperCompanies)
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| obp Surgical | CooperSurgical (CooperCompanies) | Aug 1, 2024 | Gynecological Surgery | |
| ZyMōt Fertility | CooperSurgical | Jun 10, 2024 | Undisclosed | Fertility |
| Cook Medical Reproductive Health | CooperSurgical (CooperCompanies) | Feb 7, 2022 | Undisclosed | Fertility |
| Generate Life Sciences | CooperSurgical (CooperCompanies) | Nov 10, 2021 | Reproductive Health |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — ORIGIO a/s (Fertility). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.